COMMUNIQUÉS West-GlobeNewswire

New Peer-Reviewed Publication Highlights Evidence of Mother-to-Child-Transmission of Lyme Disease Bacteria During Pregnancy and Calls for Urgent Research
09/04/2026
New paper in Frontiers in Medicine reports results of meeting of international researchers at the Banbury Center of Cold Spring Harbor Laboratory PORTOLA VALLEY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme [...]
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
09/04/2026
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical [...]
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
09/04/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
08/04/2026
PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
08/04/2026
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25 th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Thane [...]
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
08/04/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following [...]
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
08/04/2026
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
08/04/2026
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. [...]
Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026
08/04/2026
WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the [...]
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
08/04/2026
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies [...]
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
08/04/2026
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high- [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
08/04/2026
ZUG, Switzerland, April 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]
Telix Strengthens Board with Additional Director Appointments
09/04/2026
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, [...]
Option Care Health to Announce First Quarter 2026 Financial Results and Host Conference Call
08/04/2026
BANNOCKBURN, Ill., April 08, 2026 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today [...]
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2025 et de son Rapport Annuel 2025 (« Form 20-F »)
08/04/2026
Daix (France), New York City (New York, Etats-Unis), le 8 avril 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une [...]
Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution
08/04/2026
Digital solution will be designed to help guide users through injection process CINCINNATI, April 08, 2026 (GLOBE NEWSWIRE) -- Aptar Digital Health, a global leader in digital health solutions enhancing the patient [...]
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
08/04/2026
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a [...]
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
08/04/2026
WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light [...]
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
08/04/2026
AX-0810 clinical target engagement data in healthy volunteers on track for this quarter; biliary atresia selected as initial Phase 2 indication Additional programs advancing toward the clinic, including AX-0811 and AX- [...]

Pages